The National Ethical Guidelines and Research on Bromocriptine

K.Jyothsna¹, G.Vijayalakshmi²

K.jyothsna, Bhaskar Medical college, yenkapally(v),Moinabad(M), RR district, Telangana-500075. Corresponding Author: K.Jyothsna

Abstract

Bromocriptine reduces growth hormone secretion in Acromegaly. It is also effective in Parkinson disease. It is open labeled study. Single dose administration of 2.5mg Bromocriptine mesylate to patients 3 and 5 healthy volunteers to fasted condition. AUC observed normal.

Date of Submission: 13-11-2018	Date of acceptance: 28-11-2018

I. Introduction

Bromocriptine reduces growth hormone (GH) secretion in case of acromegaly and thus used. However, in normal person bromocriptine increases the GH secretion. It is well absorbed orally and have longer duration of action than levodopa. Both are highly effective in late cases of Parkinson's disease(PD). The side effects of confusion, nausea, vomiting, hallucination and postural hypotension observed. Bromocriptine is especially preferred for hyperprolactinaemia. It has adjuvant value in treatment of Diabetes Mellitus. It is used alone or dietary control and excersize.

II. Materials and Methods –Results

Open labeled, balanced and randomized study, done from jan 2018-jun 2018

Following single dose administration of Bromocriptine mesylate 3 candates to 2.5 mg to 5 healthy volunteers to fasted condition. The mean peak plasm levels of Bromocriptine, time to reach peak plasma concentration, elimination half life were $460 \text{pg/ml} \pm 225$, $2.5 \text{hrs} \pm 2.1$ and 4.25 hrs respectively. Linear relashionship was found between single dose of Bromocriptine mesylate and c-max and area under curve (AUC) in the dose range of 1 to 7.5 mg.

Following Bromocriptine mesylte 5mg administered twice daily for 14days, the Bromocriptine c-max and AUC at steady state were 630 ± 350 pg/ml and 2510 ± 1200 pg-hr/ml respectively.


III. Discussion

In clinical trials in which Bromocryptine mesylate was administered with concomittent reduction of dose of l-dopa and Carbidopa , the most common effect on-off phenomenon observed. Less common adverse effects like anorexia, nausea, headache and anxiety are observed.

It is indicated in Hyperprolactenemia and Acromegaly and Parkinson disease. Patients unresponsive to l-dopa are poor candidates for Bromocriptine. Bromocryptine is taken with food. The patient should be evaluated frequently during escalation of therapy to determine lowest dose to administer, for therapeutic response.

Acknowledgement

Thanks to conducting this study in Bhaskar Medical College. Conveying thanks to Pharmacology department, Bhaskar Medical college.



References

- [1]. [2]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM191774.pdf
- ICH (International Council for Hormonization) E-6 'guidelines for good clinical practice' Sept-2016. ICH (International Council for Hormonization) E-3 'Structure and Content of Good clinical report Sept-2016 [3].
- [4]. Ethical Principles for Medical Research involving human subjects, Declaration of Helsinki (Brazil 2013)
- [5]. The common technical document for registration of Pharmaceuticals for human use efficiency -M4E(R2), Clinical overview and clinical summary of module 2 and study reports module 5. (Sept4-2016)
- [6]. [7]. Shedule Y (ammanded version of 2014) of CDSCO(Central Drugs Standard Control Organisation)
- National Ethical Guidelines of Biomedical and Health Research involving Human Participants, ICMR (Indian council of Medical Research,2017).

K.Jyothsna, ""The National Ethical Guidelines and Research on Bromocriptine.". " IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), vol. 17, no. 11, 2018, pp 52-53.